The anti-inflammatory effect of auranofin.

Hiroi, Jun; Ohara, Kaname; Fujitsu, Takashi; Hirai, Osamu; Satoh, Sachio; Ochi, Takehiro; Senoh, Hachiro; Mori, Jo; Kikuchi, Hiroyuki

doi:10.1254/fpj.86.441

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 Type III allergic reaction 1) Reversed passive cutaneous anaphy lactic reaction (RPCAR) in rats: Four or five male Sprague-Dawley strain rats aged 8 weeks were used in each group. Reaction was induced by the method described previously (12). One ml of saline containing EA and Evans blue given i.v.…”

Section: Fr50948mentioning

confidence: 99%

“…Paw edema was induced by i.v. injection of EA solution and injection of homologous anti-EA antiserum into the subplantar region of the right hind paw according to the method described previously (12). The i.v.…”

Section: Fr50948mentioning

confidence: 99%

“…The type III al lergic reaction or complement activation is reported to be the primary cause of asthma in some patients (21,22 (12,29). Therefore, the effects on the type III reaction may play an important role in the treatment of asthma and may be predictive of clinical benefits.…”

Section: Srs Release From Neutrophils Of Ratsmentioning

confidence: 99%

See 2 more Smart Citations

Effects of FR50948, a new orally active antiallergic agent, in experimental allergic models.

et al. 1988

Self Cite

View full text Add to dashboard Cite

Abstract-The antiallergic activity of sodium 10-(2,3-dimethyl pentanamido)-4-oxo-4H-pyrimido [1,2-C] quinazoline-3-carboxylate•(hydrate(FR50948) was studied and compared with the activities of sodium cromoglycate (SCG) and lodoxamide.FR50948 had inhibitory effects on type I and type III allergic reac tions, but not on type II and IV allergic reactions.FR50948 also had weak inhi bitory effects on inflammation (carrageenin paw edema and adjuvant arthritis) and SRS release from rat neutrophils, but no antagonistic effects to histamine and serotonin.The inhibitory effect of FR50948 on IgE-mediated type I allergic reac tions was essentially the same as those of SCG and lodoxamide, because FR50948 inhibited the histamine release from rat peritoneal mast cells and had cross tachy phylaxis with SCG in the rat PCA test.However, FR50948, like lodoxamide, had a stronger activity than SCG and was effective by the oral route, unlike SCG which was effective only by the parenteral route.Furthemore, the inhibitory effects of FR50948 on type III reactions and inflammatory reactions were much more potent than those of SCG and equal to those of lodoxamide, and the effect on IgG-mediated PCA was stronger than that of either reference drug. These results suggest that FR50948 will be beneficial in clinical use.

show abstract

Section: Fr50948mentioning

confidence: 99%

Section: Fr50948mentioning

confidence: 99%

See 1 more Smart Citation

Effects of FR50948, a new orally active antiallergic agent, in experimental allergic models.

et al. 1988

Self Cite

View full text Add to dashboard Cite

show abstract

Auranofin-induced suppression of autoimmune antibody production and inflammation in genetically autoimmune-prone mice

et al. 1990

View full text Add to dashboard Cite

The gold compound auranofin and lobenzarit (CCA) were compared in regard to effects on development of an autoimmune-like disease in MRL/1 mice, which normally develop elevated levels of serum anti-DNA antibodies and rheumatoid factor as well as joint lesions similar to those seen in patients with rheumatoid arthritis. MRL/1 mice, which are genetically prone to development of autoimmune disease, were given auranofin or lobenzarit by gavage for 15 weeks, starting at 6 weeks of age. Mice were examined periodically for immunological abnormalities as well as histologic changes in articular joints. The auranofin-treated mice showed marked diminution in development of anti-DNA antibodies and serum rheumatoid factor as compared to control animals. Although higher than in the auranofin-treated animals, CCA-treated mice also had lower levels of serum autoantibodies than those seen in the control animals. Examination of limb joints for histopathologic changes indicated that the auranofin-treated animals developed only the slightest evidence of lesions as compared to control animals. CCA-treated mice also had a lessening of lesion development compared to control animals, but lesions were more developed than in auranofin-treated mice. This study indicates that auranofin is more effective than CCA in diminishing development of autoimmunity in MRL/1 mice.

show abstract

Effects of FR50948, a New Orally Active Antiallergic Agent in Experimental Allergic Models

Hiroi

Ohara

Kobayashi

et al. 1988

Japanese Journal of Pharmacology

View full text Add to dashboard Cite

The anti-inflammatory effect of auranofin.

Cited by 4 publications

References 0 publications

Effects of FR50948, a new orally active antiallergic agent, in experimental allergic models.

Effects of FR50948, a new orally active antiallergic agent, in experimental allergic models.

Auranofin-induced suppression of autoimmune antibody production and inflammation in genetically autoimmune-prone mice

Effects of FR50948, a New Orally Active Antiallergic Agent in Experimental Allergic Models

Contact Info

Product

Resources

About